Actively Recruiting
CXCR4-Targeted PET Imaging for the Differential Diagnosis of ACTH-Dependent and ACTH-Independent Cushing's Syndrome: A Prospective Observational Study
Led by Peking Union Medical College Hospital · Updated on 2026-01-20
160
Participants Needed
1
Research Sites
49 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the use of CXCR4-targeted PET/CT imaging with 68Ga-Pentixafor to improve the diagnosis of Cushing's syndrome, focusing on differentiating between ACTH-dependent and ACTH-independent types. This prospective observational study aims to assess how well this imaging method works compared to conventional techniques and, when available, 68Ga-DOTATATE PET/CT. The study is conducted by the Nuclear Medicine team at Peking Union Medical College Hospital, leveraging their expertise in neuroendocrine tumor imaging.
CONDITIONS
Brief Title
Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical suspicion or confirmed diagnosis of Cushing's syndrome based on symptoms or abnormal cortisol tests
- Able and willing to undergo PET/CT imaging with 68Ga-Pentixafor and, when applicable, 68Ga-DOTATATE
- Willing to provide informed consent for study participation
You will not qualify if you...
- Prior use of therapeutic or investigational radiopharmaceuticals within 5 physical half-lives before imaging
- Pregnancy or breastfeeding
- History of allergic reaction to gallium-based tracers or related compounds
- Clinically unstable condition or severe organ dysfunction interfering with imaging or participation
- Inability to complete required PET/CT imaging due to clinical or logistical reasons
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 day
Participants undergo PET/CT imaging with 68Ga-Pentixafor to evaluate CXCR4 expression patterns for differential diagnosis of Cushing's syndrome. Additional 68Ga-DOTATATE PET/CT scans may be performed if ectopic ACTH syndrome is suspected.
1 to 2 visits depending on imaging required
Duration - Approximately 12 months
Participants are monitored over approximately 12 months to evaluate diagnostic outcomes and disease progression.
Follow-up visits as determined by clinical need
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730
Actively Recruiting
Research Team
Z
Zhaohui Zhu, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here